In a report released yesterday, Sarah James from Piper Jaffray reiterated a Buy rating on Cigna Corp (NYSE: CI), with a price target of $215. The company’s shares closed yesterday at $188.90.
According to TipRanks.com, James is a 5-star analyst with an average return of 25.2% and a 91.1% success rate. James covers the Services sector, focusing on stocks such as Encompass Health Corporation, WellCare Health Plans, and Molina Healthcare.
Currently, the analyst consensus on Cigna Corp is a Strong Buy with an average price target of $223.33, representing a 18.2% upside. In a report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $244 price target.
.
See today’s analyst top recommended stocks >>
Based on Cigna Corp’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $11.48 billion and net profit of $806 million. In comparison, last year the company earned revenue of $10.32 billion and had a net profit of $813 million.
Based on the recent corporate insider activity of 81 insiders, corporate insider sentiment is negative on the stock. Most recently, in May 2018, Mary Hoeltzel, the VP & CAO of CI sold 1,000 shares for a total of $176,180.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cigna Corp. is a global health service company, which engages in the provision of medical, dental, disability, life and accident insurance and related products and services to businesses, governmental and non-governmental organizations and individuals.
